3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
64
INDUSTRY
12
OTHER_GOV
2
NETWORK
2
NIH
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
pembrolizumab
3
enzalutamide
3
Abiraterone Acetate
3
apalutamide
2
Topotecan
2
Testosterone
2
Itraconazole
2
Docetaxel
2
Cholecalciferol
2
Celecoxib
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
zanubrutinib
1
venetoclax
1
talabostat
1
sargramostim
1
pasireotide
1
olaparib
1
leucoselect phytosome
1
ibrutinib
1
capivasertib
1
acalabrutinib
1
abiraterone
1
Tablets
1
Streptozocin
1
Rituximab
1
Radiosurgery
1
Pluvicto
1
PT-100 dipeptide
1
Oxaliplatin
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
FED
×
zanubrutinib
×
Clear all
NCT06520098
2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled